Supplementary Figures and Tables.docx (1.97 MB)
Download file

rme-2022-0002 Supplementary Figures & Tables.docx

Download (1.97 MB)
posted on 12.04.2022, 09:52 by Julien Freitag, James Wickham, Kiran Shah, Abi Tenen



Objective: To evaluate the long-term   safety and efficacy of adipose-derived mesenchymal stem cell (ADMSC) therapy   in the treatment of knee osteoarthritis (OA).

Methods: 329 participants with knee OA   underwent intra-articular ADMSC therapy. Participants were followed up for 24-months and were separated based   on radiological OA grade.

Results: Treatment was well tolerated   with no related serious adverse events. All participant groups reported   clinically and statistically significant pain improvement. Clinical outcome was not influenced by   patients’ age or BMI. 

Conclusion: ADMSC therapy is a safe   and long-lasting effective treatment option for knee OA with the potential to   delay total joint replacement. In   addition to the observed clinical benefits, ADMSC therapy promises to reduce   the global economic burden of OA. 

Supplementary materials: 

Table 1. Adverse Events associated with abdominal   lipoharvest procedure

Table 2. Adverse Events associated with ADMSC   therapy

Table 3. Non injection related Adverse Events documented   during the 24month period of follow-up

Figure 1. Whole cohort vs. non total joint   replacement cohort outcome analysis – NPRS

Figure 2. Whole cohort vs. non total joint   replacement cohort outcome analysis – WOMAC

Figure 3. OA compartment outcome analysis - WOMAC

Figure 4. Carrier media outcome analysis - NPRS

Figure 5. Carrier media outcome analysis - WOMAC

Figure 6. Linear regression analysis of BMI vs change   in baseline WOMAC

Figure 7. Linear regression analysis of age vs change in baseline WOMAC